Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334936 | 0.90 | FKBP1A (0.69) | ALDH1A1FKBP1ARAB9APOLBHPGD | |
| SCHEMBL10245484 | 0.85 | ALDH1A1 (0.53) | ALDH1A1FKBP1ARAB9APOLBHPGD | |
| SCHEMBL14725172 | 0.79 | FKBP1A (0.75) | ALDH1A1FKBP1ARAB9APOLBHPGD | |
| SCHEMBL335399 | 0.78 | SMN1; SMN2 (0.49) | ALDH1A1RAB9AHPGDLMNAKDM4E | |
| SCHEMBL10243876 | 0.76 | FKBP1A (0.65) | ALDH1A1FKBP1ARAB9APOLBHPGD | |
| SCHEMBL335085 | 0.76 | NPC1 (0.51) | ALDH1A1RAB9APOLBMAPTLMNA | |
| SCHEMBL8284320 | 0.72 | RAB9A (0.72) | ALDH1A1FKBP1ARAB9APOLBHPGD | |
| SCHEMBL335348 | 0.71 | RAB9A (0.66) | ALDH1A1RAB9APOLBHPGDMAPT | |
| SCHEMBL13849630 | 0.71 | FKBP1A (0.76) | ALDH1A1FKBP1ARAB9APOLBHPGD | |
| SCHEMBL18575578 | 0.71 | HTR1A (0.50) | ALDH1A1MAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ALDH1A1 1939/4885FKBP1A 2222/4885RAB9A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.